Compare Ascendis Pharma A/S (ASND) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Under Armour Inc Class A — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Under Armour Inc Class A trades at $6.72 (market cap $2.86B). The key difference: Ascendis Pharma A/S is far larger — about 6.2× Under Armour Inc Class A's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| ASND | UAA | |
|---|---|---|
Market Cap | $17.74B | $2.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $8.14 |
52-Week Low | $163.32 | $4.17 |
Enterprise Value | $18.11B | $4.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Under Armour (UAA) trades at $6.79, up 3.03% today, showing technical bullish momentum with moving averages supporting upward movement. However, the company faces fundamental challenges with negative net income margins (-9.98%) and declining revenue from $5.7B in 2024 to $5.2B in 2025. Recent earnings showed mixed results with a Q1 2026 miss, while cash flow remains negative at -$362M for 2025. The Dodge collaboration and Persona AI partnership represent strategic initiatives amid ongoing North American market weakness.
The outlook remains cautious with analyst consensus price target at $5.96 below current levels, reflecting concerns about profitability and revenue trends. Investment opportunity exists if international growth and cost management improve margins, but risks include persistent North American weakness, margin pressure, and negative cash flow generation. Wall Street sentiment leans neutral with 58% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
